Imprimis obtains propriety rights for sedation, anesthetic compounded formulations

Imprimis Pharmaceuticals has acquired the rights to novel propriety sedation and analgesic/anesthetic compounded formulations for ophthalmic and other surgical procedures, according to a press release.

Variations of the formulations, administered sublingually to block pain and sedate patients, have been used in more than 1,000 cataract and refractive surgeries, co-developer John Berdahl, MD, said in the release.

“Based on our experiences to date, we believe that like our practices, others around the United States and potentially around the world, including surgical centers and hospitals, could experience significant cost savings, improvements in operating room workflow and great patient outcomes by adopting these formulations in their cataract and refractive patients’ surgeries,” he said.

The company completed an invention assignment agreement in order to acquire the rights to commercialize the formulations after finishing its intellectual property diligence process and filing a patent application with the United States Patent and Trademark Office. A patient-specific clinical evaluation is being conducted to support the commercialization of the formulations, the release said.

Imprimis hopes to make the compounded formulations for conscious sedation available for prescription and dispensing in the fall, the release said.